Skip to main content

Table 1 FDA-approved hormonal therapies for advanced hormone naïve prostate cancer and metastasis castration-resistant prostate cancer

From: Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy

Stage of prostate cancer Hormonal agent Function Year of FDA approval Reference
Advanced, hormone naïve Goserelin acetate GnRH agonist 1989 [27, 28]
Leuprolide acetate GnRH agonist 1989 [27, 29]
Histrelin acetate GnRH agonist 1991 [27, 30]
Triptorelin pamoate GnRH agonist 2000 [27, 31]
Abarelix GnRH antagonist 2003 [27, 48]
Degarelix GnRH antagonist 2008 [27, 49]
Bicalutamide AR antagonist 1995 [27, 126]
Flutamide AR antagonist 1989 [27, 127]
Castrate-resistant Abiraterone acetate CYP17 inhibitor 2011b [27, 94]
2012a [96, 99]
Enzalutamide AR antagonist 2012b [27, 101]
2014a [102, 128]
  1. GnRH gonadotropin releasing hormone, AR androgen receptor
  2. aPatients without previous treatment with docetaxel (chemotherapy naïve)
  3. bPatients treated and progressed from docetaxel (post-chemotherapy)